| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CP7A; CYP7; CYPVII |
| Entrez GeneID | 1581; |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide corresponding to a region derived from internal residues of human cytochrome P450, family 7, subfamily A, polypeptide 1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于CYP7A1抗体的参考文献概要：
---
1. **文献名称**：*"Regulation of bile acid synthesis: pathways and regulatory crosstalk"*
**作者**：Chiang JYL et al.
**摘要**：综述了CYP7A1在胆汁酸合成中的核心作用，并利用特异性抗体验证了其在肝脏中的表达受FXR和LXR转录因子调控。通过Western blot和免疫组化分析，证实高胆固醇饮食可上调CYP7A1蛋白水平。
---
2. **文献名称**：*"Antibody-based detection of CYP7A1 in human liver tissues"*
**作者**：Li T et al.
**摘要**：开发了一种高特异性兔源多克隆抗体用于检测人CYP7A1蛋白。通过免疫印迹和免疫荧光实验验证了抗体可靠性，并发现非酒精性脂肪肝患者中CYP7A1表达显著降低。
---
3. **文献名称**：*"CYP7A1 knockout mouse model reveals compensatory mechanisms in cholesterol metabolism"*
**作者**：Russell DW et al.
**摘要**：利用CYP7A1抗体在基因敲除小鼠模型中验证蛋白缺失，发现尽管CYP7A1缺失，但胆汁酸合成通过替代途径维持，抗体检测结果为代谢代偿机制提供了直接证据。
---
4. **文献名称**：*"Post-translational regulation of CYP7A1 by insulin signaling"*
**作者**：DeFabiani E et al.
**摘要**：通过特异性抗体分析发现，胰岛素通过PI3K/Akt通路抑制CYP7A1的磷酸化水平，降低其酶活性，揭示了CYP7A1在代谢综合征中的潜在作用。
---
以上文献均涉及CYP7A1抗体的实验验证，涵盖表达调控、疾病关联及技术开发方向。
The CYP7A1 antibody is a crucial tool for studying cholesterol metabolism and bile acid synthesis. CYP7A1 (cytochrome P450 family 7 subfamily A member 1) is the rate-limiting enzyme in the classic pathway of bile acid production, converting cholesterol into 7α-hydroxycholesterol in the liver. Its expression is tightly regulated by nuclear receptors (e.g., FXR, LXRα) and hormones (e.g., insulin, glucagon), linking it to lipid homeostasis, metabolic disorders, and liver diseases. Dysregulation of CYP7A1 is associated with hypercholesterolemia, gallstones, and liver fibrosis.
Researchers use CYP7A1 antibodies primarily in Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect protein levels and localization in tissues, particularly hepatocytes. These antibodies help investigate molecular mechanisms underlying metabolic syndromes, drug-induced liver injury, or circadian rhythm effects on cholesterol metabolism. Most CYP7A1 antibodies are raised against specific epitopes of human or rodent CYP7A1. with validation in knockout models to ensure specificity. Challenges include low basal expression levels in certain conditions and cross-reactivity with similar cytochrome P450 enzymes. Proper controls and tissue-specific optimization (e.g., liver vs. intestinal samples) are critical for reliable results. Recent studies also employ CYP7A1 antibodies alongside mRNA analysis (qPCR) to explore transcriptional vs. post-translational regulation in metabolic research.
×
